NCT06922097

Brief Summary

The RAPID trial is a randomized, single-center trial investigating whether giving atropine at heart rates below 60 beats per minute versus giving atropine only at heart rates below 30 beats per minute reduces the amount of norepinephrine needed to keep MAP above 65 mmHg in non-cardiac surgery patients with intraoperative bradycardia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
186

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2025

Completed
15 days until next milestone

Study Start

First participant enrolled

April 7, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 10, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 11, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2025

Completed
Last Updated

April 29, 2026

Status Verified

April 1, 2025

Enrollment Period

7 months

First QC Date

March 23, 2025

Last Update Submit

April 27, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Average norepinephrine infusion rate

    Average norepinephrine infusion rate in μg per kg actual body weight per minute (μg kg-1 min-1) needed to keep MAP above 65 mmHg from anesthetic induction until the end of surgery (continuous outcome)

    Perioperative

Secondary Outcomes (4)

  • Time-weighted average MAP <65 mmHg

    Perioperative

  • Time-weighted average heart rate <60 bpm

    Perioperative

  • Time-weighted average MAP >110 mmHg

    Perioperative

  • Time-weighted average heart rate >100 bpm

    Perioperative

Other Outcomes (5)

  • Incidence of acute kidney injury

    Within the first 3 postoperative days

  • Incidence of delirium

    Within the first 3 postoperative days

  • Incidence of urinary retention

    Within the first 3 postoperative days

  • +2 more other outcomes

Study Arms (2)

Giving atropine at heart rates below 60 beats per minute

EXPERIMENTAL
Drug: Giving atropine at heart rates below 60 beats per minute

Giving atropine at heart rates below 30 beats per minute

ACTIVE COMPARATOR
Drug: Giving atropine at heart rates below 30 beats per minute

Interventions

In patients assigned to the atropine therapy at heart rates below 60 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 60 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 60 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.

Giving atropine at heart rates below 60 beats per minute

In patients assigned to atropine therapy at heart rates below 30 beats per minute, atropine will be given at a dose of 0.5 mg when heart rate is below 30 beats per minute for one continuous minute. A second and third atropine dose of 0.5 mg will be given if heart rate remains or again drops below 30 beats per minute for one continuous minute. Patients will not be given more than 1.5 mg atropine.

Giving atropine at heart rates below 30 beats per minute

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥65 years
  • American Society of Anesthesiologists physical status III or IV
  • Chronic arterial hypertension
  • Diabetes mellitus requiring medication
  • Intraabdominal surgery
  • Preoperative renal insufficiency (serum creatinine ≥1.2 mg/dL)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Hamburg-Eppendorf

Hamburg, 20246, Germany

Location

Study Officials

  • Alina Bergholz, MD

    University Medical Centre Hamburg-Eppendorf

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

March 23, 2025

First Posted

April 10, 2025

Study Start

April 7, 2025

Primary Completion

November 11, 2025

Study Completion

December 16, 2025

Last Updated

April 29, 2026

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations